ECSP088722A - Formulaciones medicamentosas que contienen fluoroquinolonas - Google Patents

Formulaciones medicamentosas que contienen fluoroquinolonas

Info

Publication number
ECSP088722A
ECSP088722A EC2008008722A ECSP088722A ECSP088722A EC SP088722 A ECSP088722 A EC SP088722A EC 2008008722 A EC2008008722 A EC 2008008722A EC SP088722 A ECSP088722 A EC SP088722A EC SP088722 A ECSP088722 A EC SP088722A
Authority
EC
Ecuador
Prior art keywords
formulations containing
drug formulations
containing fluoroquinolones
fluoroquinolones
formulations
Prior art date
Application number
EC2008008722A
Other languages
English (en)
Inventor
Iris Heep
Kristine Fraatz
Hans-Juergen Hamann
Markus Edingloh
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP088722A publication Critical patent/ECSP088722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a formulaciones medicamentosas en forma líquida que contienen fluoroquinolonas y compuestos antioxidativos de azufre. Las formulaciones son apropiadas en especial para aplicaciones parenterales y se caracterizan, entre otras cosas, por una buena tolerancia.
EC2008008722A 2006-03-08 2008-09-08 Formulaciones medicamentosas que contienen fluoroquinolonas ECSP088722A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006010642A DE102006010642A1 (de) 2006-03-08 2006-03-08 Arzneimittelformulierungen, enthaltend Fluorchinolone

Publications (1)

Publication Number Publication Date
ECSP088722A true ECSP088722A (es) 2008-11-27

Family

ID=37907814

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008722A ECSP088722A (es) 2006-03-08 2008-09-08 Formulaciones medicamentosas que contienen fluoroquinolonas

Country Status (17)

Country Link
US (2) US20090163484A1 (es)
EP (1) EP1993549A1 (es)
JP (1) JP2009529014A (es)
KR (1) KR20080110599A (es)
CN (1) CN101400351A (es)
AU (1) AU2007222676A1 (es)
BR (1) BRPI0708692A2 (es)
CA (1) CA2644981C (es)
CR (1) CR10274A (es)
DE (1) DE102006010642A1 (es)
EC (1) ECSP088722A (es)
MX (1) MX2008011489A (es)
NZ (1) NZ571047A (es)
RU (1) RU2008139633A (es)
SV (1) SV2008003018A (es)
WO (1) WO2007101560A1 (es)
ZA (1) ZA200807486B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069493A1 (de) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid)
EP2332916A3 (en) 2009-11-19 2011-08-03 Krka Tovarna Zdravil, D.D., Novo Mesto A process for a preparation of marbofloxacin and intermediate thereof
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
CN101810569B (zh) * 2010-05-22 2011-09-21 鼎正动物药业（天津）有限公司 一种恩诺沙星注射液及其制备方法
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
KR101473979B1 (ko) * 2013-01-18 2014-12-26 한국썸벧(주) 마보플록사신을 포함하는 약제학적 조성물
GR1008168B (el) * 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
JP6358868B2 (ja) * 2014-06-17 2018-07-18 Ｄｓファーマアニマルヘルス株式会社 オルビフロキサシンを含有する製剤組成物
KR102504435B1 (ko) 2017-02-13 2023-02-27 바이엘 애니멀 헬스 게엠베하 프라도플록사신을 함유하는 액체 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
US4614572A (en) * 1985-07-08 1986-09-30 The Dow Chemical Company Liquid phase chlorination of chlorinated methanes
IN166416B (es) * 1985-09-18 1990-05-05 Pfizer
KR930001302B1 (ko) * 1990-12-07 1993-02-25 주식회사 중외제약 시플로플록사신의 주사용 조성물 및 그 제조방법
DE19500784A1 (de) * 1995-01-13 1996-07-18 Bayer Ag Enrofloxacin-Injektions- oder Infusionslösungen
WO1997023217A1 (en) * 1995-12-21 1997-07-03 Pfizer Inc. Injectable quinolone formulations
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
EP1121933A1 (en) * 2000-02-02 2001-08-08 Pfizer Products Inc. Premixed alatrofloxacin injectable compositions
OA12257A (en) * 2000-04-27 2003-11-06 Pfizer Prod Inc the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals.
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
PT1776109E (pt) * 2004-08-13 2009-03-25 Schering Plough Ltd Formulação farmacêutica que compreende um antibiótico, um triazol e um corticosteróide
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone

Also Published As

Publication number Publication date
CN101400351A (zh) 2009-04-01
JP2009529014A (ja) 2009-08-13
BRPI0708692A2 (pt) 2011-06-14
CA2644981A1 (en) 2007-09-13
WO2007101560A1 (de) 2007-09-13
MX2008011489A (es) 2008-11-14
US20150080387A1 (en) 2015-03-19
ZA200807486B (en) 2009-11-25
KR20080110599A (ko) 2008-12-18
DE102006010642A1 (de) 2007-09-27
EP1993549A1 (de) 2008-11-26
RU2008139633A (ru) 2010-04-20
US20090163484A1 (en) 2009-06-25
CA2644981C (en) 2015-04-28
CR10274A (es) 2009-03-18
NZ571047A (en) 2012-03-30
AU2007222676A1 (en) 2007-09-13
SV2008003018A (es) 2009-11-26

Similar Documents

Publication Publication Date Title
ECSP088722A (es) Formulaciones medicamentosas que contienen fluoroquinolonas
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
SV2009002858A (es) Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida
ECSP099320A (es) Compuestos de tetrahidropirrolopiracina sustituida y su aplicación en medicamentos
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR10270A (es) Medicamentos que contienen fluoroquinolonas
BRPI0819087B1 (pt) composição estabilizada, e, método para a estabilização de um produto para cuidado corporal
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
UY32187A (es) Composiciones farmaceuticas topicas
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.